News & Updates
Filter by Specialty:
Xanomeline–trospium beneficial in treatment of schizophrenia
16 Jan 2024
Treatment with the combination of xanomeline plus trospium leads to favourable reduction in positive and negative symptoms in patients with schizophrenia, while being well tolerated, according to data from the phase III EMERGENT-2 trial.
Xanomeline–trospium beneficial in treatment of schizophrenia
16 Jan 2024
NIH study: Semaglutide associated with lower risk of suicidal ideation
11 Jan 2024
byKanas Chan
Semaglutide is associated with a 49─73 percent lower risk of suicidal ideation vs other agents for treatment of obesity and type 2 diabetes mellitus (T2DM), a National Institutes of Health (NIH)─funded study has shown.
NIH study: Semaglutide associated with lower risk of suicidal ideation
11 Jan 2024
One in five community-dwelling older adults has mild neurocognitive disorders
04 Jan 2024
byKanas Chan
Mild neurocognitive disorders (NCDs) are present in one in five community-dwelling older adults in Hong Kong, while 70 percent of older adults living in residential care homes have dementia, researchers from the Chinese University of Hong Kong (CUHK) have reported.